MX2016007848A - Forma de dosificacion resistente a alteraciones con perfil de liberacion bimodal fabricado mediante co-extrusion. - Google Patents

Forma de dosificacion resistente a alteraciones con perfil de liberacion bimodal fabricado mediante co-extrusion.

Info

Publication number
MX2016007848A
MX2016007848A MX2016007848A MX2016007848A MX2016007848A MX 2016007848 A MX2016007848 A MX 2016007848A MX 2016007848 A MX2016007848 A MX 2016007848A MX 2016007848 A MX2016007848 A MX 2016007848A MX 2016007848 A MX2016007848 A MX 2016007848A
Authority
MX
Mexico
Prior art keywords
segment
dosage form
extrusion
release profile
tamper resistant
Prior art date
Application number
MX2016007848A
Other languages
English (en)
Spanish (es)
Inventor
Barnscheid Lutz
Geissler Anja
Wening Klaus
Denker Jana
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2016007848A publication Critical patent/MX2016007848A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016007848A 2013-12-16 2014-12-15 Forma de dosificacion resistente a alteraciones con perfil de liberacion bimodal fabricado mediante co-extrusion. MX2016007848A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13197503 2013-12-16
PCT/EP2014/077748 WO2015091352A1 (en) 2013-12-16 2014-12-15 Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion

Publications (1)

Publication Number Publication Date
MX2016007848A true MX2016007848A (es) 2016-09-07

Family

ID=49882823

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007848A MX2016007848A (es) 2013-12-16 2014-12-15 Forma de dosificacion resistente a alteraciones con perfil de liberacion bimodal fabricado mediante co-extrusion.

Country Status (7)

Country Link
US (3) US20150164807A1 (OSRAM)
EP (1) EP3082781A1 (OSRAM)
JP (2) JP2016540798A (OSRAM)
AU (1) AU2014365038B2 (OSRAM)
CA (1) CA2933983A1 (OSRAM)
MX (1) MX2016007848A (OSRAM)
WO (1) WO2015091352A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502077D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd Improved hme technology

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE19710008A1 (de) * 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
ES2221370T3 (es) 1998-04-03 2004-12-16 Egalet A/S Composicion de liberacion controlada.
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
ATE399538T1 (de) 2003-03-26 2008-07-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
ES2407143T3 (es) 2003-08-06 2013-06-11 Grünenthal GmbH Forma de dosificación protegida contra un posible abuso
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
PL1740156T3 (pl) 2004-04-22 2011-12-30 Gruenenthal Gmbh Sposób wytwarzania zabezpieczonej przed nadużyciem, stałej postaci aplikacyjnej
CA2572352A1 (en) 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
PL1765298T3 (pl) 2004-07-01 2013-01-31 Gruenenthal Gmbh Sposób wytwarzania stałej postaci dawkowania, która jest zabezpieczona przez nadużywaniem, wykorzystujący wytłaczarkę z przekładnią planetarną
WO2006002884A1 (de) 2004-07-01 2006-01-12 Grünenthal GmbH Gegen missbrauch gesicherte, orale darreichtungsform
JP4563787B2 (ja) * 2004-12-10 2010-10-13 日立プラズマディスプレイ株式会社 プラズマディスプレイ装置及びその制御方法
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1895989A2 (en) 2005-06-03 2008-03-12 Egalet A/S A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
EP1991207A2 (en) * 2006-01-21 2008-11-19 Abbott GmbH & Co. KG Dosage form and method for the delivery of drugs of abuse
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
AU2008207200B2 (en) 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
JP2010527285A (ja) * 2007-04-26 2010-08-12 シグモイド・ファーマ・リミテッド 複数のミニカプセルの製造
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
JP5774853B2 (ja) * 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
BRPI0920082A2 (pt) 2008-10-27 2019-09-24 Alza Corp forma de dosagem oral de acetaminofeno/tramadol com liberação estendida.
NZ594071A (en) 2009-01-26 2013-01-25 Egalet Ltd Controlled release formulations comprising morphine sulphate for continuous treatment of pain
NZ594208A (en) 2009-02-06 2012-10-26 Egalet Ltd Pharmaceutical compositions resistant to abuse
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
WO2011009602A1 (en) * 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
HRP20181716T1 (hr) * 2012-04-18 2018-12-28 Grünenthal GmbH Farmaceutski oblik doziranja otporan na zlonamjernu uporabu i naglo oslobađanje cjelokupne doze
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc

Also Published As

Publication number Publication date
US20150164807A1 (en) 2015-06-18
US20160338976A1 (en) 2016-11-24
WO2015091352A1 (en) 2015-06-25
EP3082781A1 (en) 2016-10-26
AU2014365038A1 (en) 2016-06-30
JP2016540798A (ja) 2016-12-28
CA2933983A1 (en) 2015-06-25
US20180221307A1 (en) 2018-08-09
JP2019172688A (ja) 2019-10-10
AU2014365038B2 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
MX2015016254A (es) Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
BR112015026549A2 (pt) forma de dosagem à prova de violação contendo uma ou mais partículas
IL262581B1 (en) Production methods, preparations and medical applications of drugs containing cannabis for oral administration
BRPI0906467C1 (pt) forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
EA201890130A1 (ru) Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
BR112018071155A2 (pt) formas de dosagem de antagonista opioide de liberação modificada
BR112014019988A8 (pt) Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
PH12013501994A1 (en) Controlled release pharmaceutical dosage forms
BR112015017451A2 (pt) formulações farmacêuticas resistentes à violação
BR112017028140A2 (pt) formulações farmacêuticas
ES2425315R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
CU20190060A7 (es) Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 útiles en el tratamiento de trastornos respiratorios
BR112017009521A2 (pt) comprimido de múltiplas camadas que contém um fármaco instável à luz
EP3377043A4 (en) DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
IL280083A (en) A pharmaceutical dosage form that can be administered orally and with a modified release
PH12016501039B1 (en) Pharmaceutical dosage forms
EA201991265A1 (ru) Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат
MX2016007848A (es) Forma de dosificacion resistente a alteraciones con perfil de liberacion bimodal fabricado mediante co-extrusion.
MX2015014307A (es) Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados.
BR112017022335A2 (pt) combinação de dose fixa inviolável que fornece rápida liberação de dois fármacos a partir de partículas e matriz
BR112017022855A2 (pt) combinação de dose fixa inviolável que provê liberação rápida de dois fármacos a partir de partículas e um pó
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
PH12020500295A1 (en) Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same
CL2017000026A1 (es) Formas de dosificación farmacéutica